Filtered By:
Source: Circulation
Condition: Heart Failure
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 195 results found since Jan 2013.
Mutant Phosphodiesterase 3A Protects From Hypertension-Induced Cardiac Damage
CONCLUSIONS: Although in vascular smooth muscle, PDE3A mutations cause hypertension, they confer protection against hypertension-induced cardiac damage in hearts. Nonselective PDE3A inhibition is a final, short-term option in heart failure treatment to increase cardiac cAMP and improve contractility. Our data argue that mimicking the effect of PDE3A mutations in the heart rather than nonselective PDE3 inhibition is cardioprotective in the long term. Our findings could facilitate the search for new treatments to prevent hypertension-induced cardiac damage.PMID:36259389 | DOI:10.1161/CIRCULATIONAHA.122.060210
Source: Circulation - October 19, 2022 Category: Cardiology Authors: Maria Ercu Michael B M ücke Tamara Pallien Lajos Mark ó Anastasiia Sholokh Carolin Sch ächterle Atakan Aydin Alexa Kidd Stephan Walter Yasmin Esmati Brandon J McMurray Daniella F Lato Daniele Yumi Sunaga-Franze Philip H Dierks Barbara Isabel Montesinos Source Type: research
State of the Science: The Relevance of Symptoms in Cardiovascular Disease and Research: A Scientific Statement From the American Heart Association
Circulation. 2022 Aug 18:101161CIR0000000000001089. doi: 10.1161/CIR.0000000000001089. Online ahead of print.ABSTRACTSymptoms of cardiovascular disease drive health care use and are a major contributor to quality of life. Symptoms are of fundamental significance not only to the diagnosis of cardiovascular disease and appraisal of response to medical therapy but also directly to patients' daily lives. The primary purpose of this scientific statement is to present the state of the science and relevance of symptoms associated with cardiovascular disease. Symptoms as patient-reported outcomes are reviewed in terms of the genes...
Source: Circulation - August 18, 2022 Category: Cardiology Authors: Corrine Y Jurgens Christopher S Lee Dawn M Aycock Ruth Masterson Creber Quin E Denfeld Holli A DeVon Linda R Evers Miyeon Jung Gianluca Pucciarelli Megan M Streur Marvin A Konstam American Heart Association Council on Cardiovascular and Stroke Nursing; Co Source Type: research
Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden
CONCLUSIONS: Patients with recently diagnosed atrial fibrillation and CHA2DS2-VASc score ≥4 should be considered for ERC to reduce cardiovascular outcomes, whereas those with fewer comorbidities may have less favorable outcomes with ERC.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT01288352; URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2010-021258-20; URL: https://www.isrctn.com/; Unique identifier: ISRCTN04708680.PMID:35968706 | DOI:10.1161/CIRCULATIONAHA.122.060274
Source: Circulation - August 15, 2022 Category: Cardiology Authors: Andreas Rillig Katrin Borof G ünter Breithardt A John Camm Harry J G M Crijns Andreas Goette Karl-Heinz Kuck Andreas Metzner Panos Vardas Eik Vettorazzi Karl Wegscheider Antonia Zapf Paulus Kirchhof Source Type: research
Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection Fraction
CONCLUSIONS: Patients with HFpEF in whom LVEF ranged from 50% to 60% demonstrated reduced contractility, impaired ventriculo-arterial coupling, and higher extracellular volume fraction. In contrast, patients with HFpEF and a LVEF >60% demonstrated a hypercontractile state with excessive LV afterload and diminished preload reserve. A LVEF-based stratification of patients with HFpEF identified distinct morphologic and pathophysiologic subphenotypes.PMID:35862208 | DOI:10.1161/CIRCULATIONAHA.122.059280
Source: Circulation - July 21, 2022 Category: Cardiology Authors: Sebastian Rosch Karl-Patrik Kresoja Christian Besler Karl Fengler Anne Rebecca Sch öber Maximilian von Roeder Christian L ücke Matthias Gutberlet Karin Klingel Holger Thiele Karl-Philipp Rommel Philipp Lurz Source Type: research
Cost-Effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical Trial
CONCLUSION: Catheter ablation of atrial fibrillation was economically attractive compared with drug therapy in the CABANA Trial overall at present benchmarks for health care value in the United States on the basis of projected incremental QALYs but not LYs alone.PMID:35726631 | DOI:10.1161/CIRCULATIONAHA.122.058575
Source: Circulation - June 21, 2022 Category: Cardiology Authors: Derek S Chew Yanhong Li Patricia A Cowper Kevin J Anstrom Jonathan P Piccini Jeanne E Poole Melanie R Daniels Kristi H Monahan Linda Davidson-Ray Tristram D Bahnson Hussein R Al-Khalidi Kerry L Lee Douglas L Packer Daniel B Mark CABANA Investigators Source Type: research
Association of Neighborhood-Level Material Deprivation With Atrial Fibrillation Care in a Single-Payer Health Care System: A Population-Based Cohort Study
CONCLUSIONS: Despite universal health care and prescription medication coverage, residents of more deprived neighborhoods were less likely to visit cardiologists or receive rhythm control interventions after AF diagnosis, even though they exhibited higher cardiovascular disease burden and higher risk of adverse outcomes.PMID:35678171 | DOI:10.1161/CIRCULATIONAHA.122.058949
Source: Circulation - June 9, 2022 Category: Cardiology Authors: Husam Abdel-Qadir Leo E Akioyamen Jiming Fang Andrea Pang Andrew C T Ha Cynthia A Jackevicius David A Alter Peter C Austin Clare L Atzema R Sacha Bhatia Gillian L Booth Sharon Johnston Irfan Dhalla Moira K Kapral Harlan M Krumholz Candace D McNaughton Ida Source Type: research
Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure
Conclusions: In patients with HFpEF/HFmrEF, the presence of latent PVD uncovered by invasive hemodynamic exercise testing identifies patients who may worsen with atrial shunt therapy, whereas those without latent PVD may benefit.PMID:35354306 | DOI:10.1161/CIRCULATIONAHA.122.059486
Source: Circulation - March 31, 2022 Category: Cardiology Authors: Barry A Borlaug John Blair Martin W Bergmann Heiko Bugger Dan Burkhoff Leonhard Bruch David S Celermajer Brian Claggett John G F Cleland Donald E Cutlip Ira Dauber Jean-Christophe Eicher Qi Gao Thomas M Gorter Finn Gustafsson Chris Hayward Jan Van der Hey Source Type: research
Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association
CONCLUSIONS: The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.PMID:35078371 | DOI:10.1161/CIR.0000000000001052
Source: Circulation - January 26, 2022 Category: Cardiology Authors: Connie W Tsao Aaron W Aday Zaid I Almarzooq Alvaro Alonso Andrea Z Beaton Marcio S Bittencourt Amelia K Boehme Alfred E Buxton April P Carson Yvonne Commodore-Mensah Mitchell S V Elkind Kelly R Evenson Chete Eze-Nliam Jane F Ferguson Giuliano Generoso Jen Source Type: research
